TECH OUTLOOK 6APRIL - 2022EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comWith a growing need for faster go-to-market times, the pharma industry is on the verge of disruptive transformation. The increasing prevalence of chronic diseases has also raised the global demand for effective therapies, which calls for quality healthcare products. In light of this, the increasing need to launch high-quality products at reduced prices has become one of the major drivers in the pharma arena. This is in line with the global contract manufacturing organisation (CMO) market's 2021 valuation of $183.62 billion, which is projected to reach $289.64 billion by 2027.Essentially, the increasing demand for pharmaceutical products with potential applications in the treatment of various diseases and pandemic-related shortages of lifesaving medicines has mandated the outsourcing of manufacturing operations. A prime example of this enhanced significance of outsourced manufacturing is the movement toward injectable media, which is driving a majority of pharma firms to acquire allied injectable manufacturing companies and increase their production capabilities. In the coming years, the demand for CMOs is set to surge as pharma companies are poised to place significant emphasis on R&D and innovation.In this edition of Pharma Tech Outlook, we bring you some of the most prominent contract manufacturing organisations that deliver the best outcomes for their clients. This edition also combines thought leadership from subject matter experts for aspiring CXOs in the pharma sector. We hope this edition provides you with the right assistance in choosing the best contract manufacturing organisration according to your requirements. Do let us know your thoughts!Impact of CMOs on Pharma ManufacturingTECH OUTLOOKTECH OUTLOOKCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.APRIL 04, 2022, Vol 08 - Issue 11 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:David Parker
< Page 5 | Page 7 >